Morphic Holding

Morphic Holding FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Morphic Holding (MORF) as of Oct 22, 2026 is 74.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 171.65 % — a change of -56.50% (lower).

FCF Conversion

74.66 %

YoY

-56.50%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Morphic Holding is 2023 74.66 % . FCF Conversion Rate (FCF/EBITDA) of Morphic Holding was 2022 171.65 % . It decreases by -56.50% lower compared to the previous year.

The Morphic Holding FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
96.69 USD
Jan 1, 2018
-317.56 USD
Jan 1, 2019
101.11 USD
Jan 1, 2020
103.41 USD
Jan 1, 2021
89.64 USD
Jan 1, 2022
171.65 USD
Jan 1, 2023
74.66 USD
The Morphic Holding FCF Conversion history
YEARFCF ConversionYoY
74.66 %-56.50%
171.65 %+91.47%
89.64 %-13.31%
103.41 %+2.28%
101.11 %-131.84%
-317.56 %-428.43%
96.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Morphic Holding Stock analysis

What does Morphic Holding do? Morphic Holding Inc. is a pharmaceutical company that focuses on developing therapies for serious diseases. The company was founded in 2015 and is based in Waltham, Massachusetts. The company's business model is centered around developing drugs based on "Morphic Molecules" that are specifically designed to interact with certain target proteins in the body. These molecules aim to improve the treatment of diseases such as autoimmune diseases and fibrosis. Morphic Holding Inc. collaborates closely with leading scientists in the field of structural biology to develop new therapy options for patients. The company has formed partnerships with Biogen, Janssen Biotech, and AbbVie to collaboratively develop new medications. In addition to partnering with other leading companies in the healthcare industry, Morphic Holding Inc. also maintains its own research department focused on the discovery and development of new compounds. The company has applied for and been granted several patents for its "Morphic Molecules," further strengthening its ability to develop innovative therapies for serious diseases. One of Morphic Holding Inc.'s current products is a drug for the treatment of cystic fibrosis that is still in the development phase. The company is working to advance its research and development in this area to continue offering innovative therapies for patients. Morphic Holding Inc. is also involved in biotechnological development and offers services to assist other companies in developing new compounds. These services include the identification and validation of target proteins, the design and synthesis of molecules, and the optimization of drug properties. In conclusion, Morphic Holding Inc. is an emerging force in the pharmaceutical development field. The company has a unique approach to drug development and has already established partnerships with other companies and leading research institutions to develop new therapy options for patients. With its commitment to innovation and research, Morphic Holding Inc. is likely to continue making significant advancements in the field of medicine in the future. Morphic Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Morphic Holding stock

FCF Conversion Rate (FCF/EBITDA) of Morphic Holding is 74.66 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Morphic Holding changed from 171.65 % to 74.66 %, representing a -56.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Morphic Holding since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Morphic Holding with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Morphic Holding

All Key Metrics — Morphic Holding